Diabetes (type 2) - empagliflozin [ID641]: evaluation report

Contents:

01 - Pre-Meeting Briefing prepared by NICE

02 - Pre-Meeting Briefing - Appendices prepared by NICE

03 - Submission from the technology manufacturer - Boehringer Ingelheim

04 - NICE request to the manufacturer for clarification on their submission

05 - Manufacturer clarification response

06 - Consultee submission - ABCD and RCP

07 - Consultee submission – RCN

08 - Clinical expert personal perspective – Sathyapalan

09 - Clinical expert personal perspective – Winocour

10 - Patient expert personal perspective – Kuti

11 - Evidence Review Group report prepared by Warwick Evidence

12 - Evidence Review Group replacement page

13 - Evidence Review Group report addendum

14 - Manufacturer factual accuracy check of Evidence Review Group report

 

Please note: the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 27 August 2014